Följ
Mark Rozenbaum
Mark Rozenbaum
Verifierad e-postadress på pfizer.com
Titel
Citeras av
Citeras av
År
The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis
MH Rozenbaum, P Pechlivanoglou, TS Van Der Werf, JR Lo-Ten-Foe, ...
European journal of clinical microbiology & infectious diseases 32, 305-316, 2013
1612013
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
MJJ Mangen, MH Rozenbaum, SM Huijts, CH van Werkhoven, ...
European Respiratory Journal 46 (5), 1407-1416, 2015
1442015
Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 …
MH Rozenbaum, EAM Sanders, AJ van Hoek, AGSC Jansen, ...
Bmj 340, 2010
1422010
Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis
MH Rozenbaum, MJJ Mangen, SM Huijts, TS van der Werf, MJ Postma
Vaccine 33 (28), 3193-3199, 2015
1392015
Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines
S Vegter, C Boersma, M Rozenbaum, B Wilffert, GJ Navis, MJ Postma
Pharmacoeconomics 26, 569-587, 2008
1122008
Stem cell-related cardiac gene expression early after murine myocardial infarction
S Vandervelde, MJA van Luyn, MH Rozenbaum, AH Petersen, RA Tio, ...
Cardiovascular research 73 (4), 783-793, 2007
972007
Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses
TA Westra, MH Rozenbaum, RM Rogoza, HW Nijman, T Daemen, ...
Journal of Infectious Diseases 204 (3), 377-384, 2011
882011
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
MH Rozenbaum, AJ Van Hoek, D Fleming, CL Trotter, E Miller, ...
Bmj 345, 2012
842012
Burden of early, advanced and metastatic breast cancer in The Netherlands
GT Vondeling, GL Menezes, EP Dvortsin, FGA Jansman, IR Konings, ...
BMC cancer 18, 1-11, 2018
832018
The impact of patent expiry on drug prices: a systematic literature review
GT Vondeling, Q Cao, MJ Postma, MH Rozenbaum
Applied health economics and health policy 16, 653-660, 2018
802018
Cost–effectiveness of varicella vaccination programs: an update of the literature
MH Rozenbaum, AJ Van Hoek, S Vegter, MJ Postma
Expert review of vaccines 7 (6), 753-782, 2008
672008
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged≥ 65 years in the Netherlands
MH Rozenbaum, E Hak, TS van der Werf, MJ Postma
Clinical therapeutics 32 (8), 1517-1532, 2010
602010
Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands
MJ Meijboom, MH Rozenbaum, A Benedictus, W Luytjes, MCJ Kneyber, ...
Vaccine 30 (31), 4691-4700, 2012
492012
Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world
MJ Postma, M Jit, MH Rozenbaum, B Standaert, HA Tu, RCW Hutubessy
BMC medicine 9, 1-11, 2011
482011
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations
S Vegter, MH Rozenbaum, R Postema, K Tolley, MJ Postma
Clinical Therapeutics 32 (9), 1651-1661, 2010
482010
Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
MH Rozenbaum, MJJ Mangen, C Giaquinto, JC Wilschut, E Hak, ...
BMC Public Health 11, 1-12, 2011
472011
Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
RE Lauppe, JL Hansen, C Gerdesköld, MH Rozenbaum, AM Strand, ...
Open Heart 8 (2), e001755, 2021
402021
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands
J Stevanović, M Pompen, HH Le, MH Rozenbaum, RG Tieleman, ...
PLoS One 9 (8), e103974, 2014
392014
On discounting of health gains from human papillomavirus vaccination: effects of different approaches
TA Westra, M Parouty, WB Brouwer, PH Beutels, RM Rogoza, ...
Value in Health 15 (3), 562-567, 2012
392012
Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries
HAT Tu, MH Rozenbaum, PC Coyte, SC Li, HJ Woerdenbag, MJ Postma
Vaccine 30 (8), 1521-1528, 2012
392012
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20